Hemostatic considerations for gender affirming care

Gender dysphoria or gender incongruence is defined as “persons that are not satisfied with their designated gender” [1]. The awareness and evidence-based treatment options available to this population have grown immensely over the last two decades. Protocols now include an Endocrine Society Clinical Practice Guideline [1] as well as the World Profe ssional Association of Transgender Health Standards of Care (WPATH SOC) [2]. Hematologic manifestations, most notably thrombosis, are one of the most recognized adverse reactions to the hormones used for gender-affirming care.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Review Article Source Type: research